Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA Issues FY 2013 Revenue Guidance Below Analysts Estimates; Issues FY 2013 Operating Margin and Net Debt Guidance
Guerbet SA announced that its annual revenues for fiscal year 2013 are expected to range between EUR 395 million and EUR 405 million. Overall, the current operating margin is expected in consequence to range between 6.5% and 7.5% and net debt to remain under EUR 100 million in fiscal year 2013. According to I/B/E/S Estimates, analysts on average had been expecting the company to report fiscal year 2013 revenue of EUR 416.8 million
Latest Developments for Guerbet SA
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
- Guerbet launches CE-marked FlowSens solution on global markets
- Guerbet SA receives FDA approval for new manufacturing plant for Lipiodol injection
- Share this
- Digg this